Nathan J. Dowden, Chief Operating Officer at Entrada Therapeutics, Inc. (TRDA), sold 1,408 shares at $13.43 ($19K) on 2023-09-06, disclosed to the SEC on 2023-09-06.
Scheduled sale ($19k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.46 | 436 | $6K | 32.5% |
| 2 | $13.43 | 913 | $12K | 63.2% |
| 3 | $14.01 | 59 | $827 | 4.3% |
| Total | $13.77 avg | 1,408 | $19K | 100% |
| Filing → |
| TRDA | SELL | 2024-09-30 | $14K | — | Filing → |
| TRDA | SELL | 2024-09-10 | $35K | — | Filing → |
| TRDA | SELL | 2024-08-20 | $873K | — | Filing → |